does not contaminate 225Ac. Actinium metal has been prepared by the reduction of actinium fluoride with lithium vapor in vacuum at a temperature between 1100 and 1300 °C. Higher temperatures resulted in evaporation of the product and lower ones lead to an incomplete transformation. Lithium was chosen among other alkali metals because its fluoride is most volatile. Applications Owing to its scarcity, high price and radioactivity, 227Ac currently has no significant industrial use, but 225Ac is currently being studied for use in cancer treatments such as targeted alpha therapies. 227Ac is highly radioactive and was therefore studied for use as an active element of radioisotope thermoelectric generators, for example in spacecraft. The oxide of 227Ac pressed with beryllium is also an efficient neutron source with the activity exceeding that of the standard americium-beryllium and radium-beryllium pairs. In all those applications, 227Ac (a beta source) is merely a progenitor which generates alpha-emitting isotopes upon its decay. Beryllium captures alpha particles and emits neutrons owing to its large cross-section for the (α,n) nuclear reaction: ^{9}_{4}Be + ^{4}_{2}He -> ^{12}_{6}C + ^{1}_{0}n + \gamma The 227AcBe neutron sources can be applied in a neutron probe – a standard device for measuring the quantity of water present in soil, as well as moisture/density for quality control in highway construction. Such probes are also used in well logging applications, in neutron radiography, tomography and other radiochemical investigations. 225Ac is applied in medicine to produce in a reusable generator or can be used alone as an agent for radiation therapy, in particular targeted alpha therapy (TAT). This isotope has a half-life of 10 days, making it much more suitable for radiation therapy than 213Bi (half-life 46 minutes). Additionally, 225Ac decays to nontoxic 209Bi rather than stable but toxic lead, which is the final product in the decay chains of several other candidate isotopes, namely 227Th, 228Th, and 230U. Not only 225Ac itself, but also its daughters, emit alpha particles which kill cancer cells in the body. The major difficulty with application of 225Ac was that intravenous injection of simple actinium complexes resulted in their accumulation in the bones and liver for a period of tens of years. As a result, after the cancer cells were quickly killed by alpha particles from 225Ac, the radiation from the actinium and its daughters might induce new mutations. To solve this problem, 225Ac was bound to a chelating agent, such